Latest Period
Q1 2026
Security Snapshot
Drugs Made In America Acquisition Corp. - Common Shares (DMAA) Institutional Ownership
CUSIP: G2847J104
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
38
Shares (Excl. Options)
22,514,907
Price
$10.48
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares
- Symbol
- DMAA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 22,514,907
- Total 13F value
- $236,043,075
- Portfolio coverage rank
- 0%
- Share change
- -130,144
- Value change
- -$929,603
- Number of holders
- 38
- Shares outstanding
- 33,333,333
- SEC-reported price per share
- $10.54
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DMAA - Drugs Made In America Acquisition Corp. - Common Shares is tracked under CUSIP G2847J104.
- 38 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 38 to 38 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $231,075,647 to $236,043,075.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 38 institutions filings for Q1 2026.
Security key
G2847J104
Latest holder period
Q1 2026
13F holders
38
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
DMAA full holder history
Drugs Made In America Acquisition Corp. SEC filings
Drugs Made In America Acquisition Corp. company facts
Drugs Made In America Acquisition Corp. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G2847J104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
DMAA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Drugs Made In America Acquisition LLC | 12% | $42,139,127 | 4,188,780 | Drugs Made In America Acquisition LLC | 18 Feb 2025 | |||
| Karpus Management, Inc. | 8.2% | +18% | $27,989,912 | +$4,284,765 | 2,744,109 | +18% | KARPUS MANAGEMENT, INC. | 30 Jun 2025 |
| First Trust Capital Management L.P. | 6.2% | $20,791,022 | 2,066,702 | First Trust Capital Management L.P. | 31 Mar 2025 | |||
| MIZUHO FINANCIAL GROUP INC | 6% | $20,985,000 | 2,000,000 | Mizuho Financial Group, Inc. | 31 Mar 2026 | |||
| Polar Asset Management Partners Inc. | 5.7% | $19,114,000 | 1,900,000 | Polar Asset Management Partners Inc. | 31 Mar 2025 | |||
| GLAZER CAPITAL, LLC | 5.4% | $18,338,897 | 1,822,952 | Glazer Capital, LLC | 31 Mar 2025 | |||
| Hudson Bay Capital Management LP | 4.6% | -15% | $15,918,500 | -$2,567,500 | 1,550,000 | -14% | Hudson Bay Capital Management LP | 30 Sep 2025 |
As of 31 Mar 2026, 38 institutional investors reported holding 22,514,907 shares of Drugs Made In America Acquisition Corp. - Common Shares (DMAA). This represents 68% of the company’s total 33,333,333 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
65%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Karpus Management, Inc. | 7.6% | 2,530,517 | -0.32% | 0.83% | $26,519,818 |
| First Trust Capital Management L.P. | 6.7% | 2,242,500 | 0% | 1.2% | $23,501,400 |
| MIZUHO SECURITIES USA LLC | 6% | 2,000,000 | +40% | 0.49% | $20,900,000 |
| GLAZER CAPITAL, LLC | 5% | 1,678,406 | -7.6% | 0.38% | $17,590,000 |
| Westchester Capital Management, LLC | 5% | 1,669,000 | 0% | 0.85% | $17,524,500 |
| Polar Asset Management Partners Inc. | 4.8% | 1,600,000 | 0% | 0.4% | $16,768,000 |
| WOLVERINE ASSET MANAGEMENT LLC | 4.7% | 1,553,708 | +19% | 0.25% | $16,313,934 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 4% | 1,323,351 | 0.89% | $13,881,952 | |
| ARISTEIA CAPITAL, L.L.C. | 2.6% | 881,716 | 0% | 0.21% | $9,240,384 |
| D. E. Shaw & Co., Inc. | 2.1% | 690,000 | 0% | 0.01% | $7,245,000 |
| HEIGHTS CAPITAL MANAGEMENT, INC | 2% | 650,000 | 0% | 1.9% | $6,825,000 |
| Shaolin Capital Management LLC | 1.7% | 550,000 | +172% | 0.48% | $5,764,000 |
| Radcliffe Capital Management, L.P. | 1.6% | 546,808 | 0% | 0.44% | $5,738,750 |
| LMR Partners LLP | 1.5% | 500,000 | 0% | 0.05% | $5,240,000 |
| RIVERNORTH CAPITAL MANAGEMENT, LLC | 1.3% | 417,998 | 0% | 0.22% | $4,380,619 |
| WHITEBOX ADVISORS LLC | 1.2% | 400,000 | 0% | 0.06% | $4,192,000 |
| METEORA CAPITAL, LLC | 1.1% | 380,299 | 0.29% | $3,985,534 | |
| AQR Arbitrage LLC | 1.1% | 357,585 | -3.7% | 0.06% | $3,754,643 |
| RLH Capital LLC | 0.95% | 316,551 | 0% | 1.7% | $3,322,203 |
| Hudson Bay Capital Management LP | 0.89% | 297,833 | -81% | 0.02% | $3,127,247 |
| Quarry LP | 0.8% | 266,551 | 0% | 0.57% | $2,797,453 |
| Governors Lane LP | 0.75% | 250,000 | 0% | 0.33% | $2,623,750 |
| Context Capital Management, LLC | 0.75% | 250,000 | 0% | 0.06% | $2,623,750 |
| TORONTO DOMINION BANK | 0.61% | 203,838 | +1.9% | 0% | $2,136,222 |
| L1 Global Manager Pty Ltd | 0.6% | 200,000 | 0% | 1.7% | $2,096,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q1 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 22,514,907 | $236,043,075 | -$929,603 | $10.48 | 38 |
| 2025 Q4 | 22,313,763 | $231,075,647 | +$10,437,875 | $10.37 | 38 |
| 2025 Q3 | 22,407,322 | $230,112,841 | +$8,645,514 | $10.27 | 38 |
| 2025 Q2 | 20,823,195 | $212,304,432 | +$35,784,995 | $10.20 | 32 |
| 2025 Q1 | 16,949,502 | $169,795,617 | +$169,795,617 | $10.02 | 23 |